Quick answer: Sermorelin and ipamorelin both raise growth hormone release, but they act on two different receptor systems. Sermorelin is a growth hormone releasing hormone analog that works on the GHRH receptor, the same receptor the body's own releasing hormone uses. Ipamorelin is a ghrelin receptor agonist, a growth hormone secretagogue that was designed to be more selective than older compounds in its class, which raised cortisol and prolactin in early studies. Much of the comparative ipamorelin evidence comes from animal work and small early-phase human studies rather than large long-term human trials, and a licensed prescriber decides whether either compound is appropriate.
Sermorelin and ipamorelin get grouped together because they share an outcome, more growth hormone in circulation, and that shared outcome hides how differently they get there. Understanding the two receptor systems is the part that actually explains why clinicians treat them differently and why the evidence behind them is not equally mature. Everything below is a description of mechanism and evidence, not a recommendation, because a prescription follows a clinical evaluation and nothing else.
How each compound signals the pituitary
Sermorelin is a shortened analog of growth hormone releasing hormone, the peptide the hypothalamus sends to the pituitary to trigger a release pulse. Binding at the GHRH receptor means sermorelin is essentially amplifying a signal the body already sends on its own schedule. Release stays subject to somatostatin, the braking hormone that shuts pulses down, so the pituitary retains its normal veto.
Ipamorelin approaches the same gland from a different door. Acting as an agonist at the ghrelin receptor, sometimes described in the literature as the growth hormone secretagogue receptor, ipamorelin mimics a hunger-associated signal that also drives growth hormone release. Ghrelin receptor activity additionally dampens somatostatin tone, which is the pharmacological argument for why the two mechanisms are sometimes described as complementary.
What selectivity means in ipamorelin's case
Selectivity is the single claim made most often about ipamorelin, and it has a specific historical meaning. Earlier growth hormone secretagogues reliably raised growth hormone but also nudged cortisol and prolactin upward in study subjects, which is an unwanted effect if the target is the growth hormone axis alone. Ipamorelin was characterized in preclinical work as producing growth hormone release with comparatively little effect on those other hormones.
Selectivity established in animal models is a reasonable starting point and not the same thing as an established human safety profile. Long-term human data on ipamorelin in healthy adults is thin, and most of what exists comes from small studies with short follow-up windows or from clinical observation rather than controlled trials. Reading a selectivity claim as proof of long-term safety in people is the most common overreach in peptide marketing.
Where the human evidence is stronger and weaker
Growth hormone releasing hormone as a class has the longer human research history, including work in adults on how GHRH analogs affect the growth hormone axis and how that axis changes with adult age. Sermorelin is dispensed today as a compounded medication, which is not FDA approved, meaning the formulation has not gone through FDA review for safety, effectiveness, or manufacturing consistency. Any provider implying otherwise is misinforming you.
Ipamorelin never reached approval anywhere and its published human record is smaller, concentrated in early-phase pharmacology and in a trial of postoperative gut motility that did not meet its endpoints. Anyone comparing the two honestly has to say that the depth of human evidence differs, not merely the mechanism. For a fuller account of how growth hormone peptides differ from injected growth hormone itself, the comparison of sermorelin and synthetic growth hormone covers the regulatory and physiologic split in detail.
Pulsatility, feedback, and why clinicians care
Growth hormone is not secreted at a steady level in healthy adults; it comes in pulses, with the largest ones occurring during deep slow wave sleep. Preserving that pulsed pattern is the reason clinicians often favor compounds that work upstream of the pituitary rather than replacing the hormone outright. Sermorelin has a short half life measured in minutes, which produces a brief pulse rather than a sustained elevation.
Ipamorelin also produces a pulse rather than a plateau, which is part of why it is often discussed alongside sermorelin rather than in opposition to it. Whether a given person's growth hormone axis responds usefully to either signal depends on pituitary function, which is exactly what a clinical evaluation and lab work exist to assess. A compound that depends on a working pituitary does nothing useful for someone whose pituitary is the problem.
What a prescriber weighs when choosing
Choosing between compounds is a clinical judgment built on your history, your labs, and what symptoms actually brought you in. A prescriber may conclude that neither compound is appropriate, or that another condition should be ruled out first. Thyroid function, testosterone status, iron levels, sleep apnea, and mood disorders all produce symptoms people attribute to declining growth hormone.
Compound selection is also constrained by what a licensed pharmacy will dispense against a valid prescription, a narrower list than what the wider internet offers. The gap between those two lists is the subject of the difference between prescription peptides and research-use-only products, and it matters more for your safety than any mechanism debate.
Frequently Asked Questions
Is ipamorelin stronger than sermorelin?
Strength is the wrong frame for comparing these two, because the compounds act on separate receptors and are studied under different conditions, so head-to-head potency claims usually come from marketing rather than trials. Published comparisons in humans are limited, and animal data does not transfer cleanly to adult men. A prescriber evaluates fit rather than ranking compounds by strength.
Can sermorelin and ipamorelin be used together?
Combining a GHRH analog with a ghrelin receptor agonist is sometimes described as pairing complementary pathways, but human evidence for combined use is thin and comes mostly from small studies and clinical observation. Adding compounds also adds variables if something does not agree with you. Any combination is a decision for a licensed prescriber, and the simpler option is frequently the better one.
Does ipamorelin raise cortisol?
Ipamorelin was characterized in preclinical studies as having comparatively little effect on cortisol and prolactin, which distinguished it from older secretagogues in its class. Preclinical characterization is not the same as confirmed human safety over long periods, and that distinction is worth holding onto. Report any new symptoms to your prescriber rather than assuming a selectivity claim covers you.
Is ipamorelin FDA approved?
Ipamorelin is not an FDA-approved medication, and neither is compounded sermorelin as dispensed today. Compounded medications are prepared by licensed pharmacies against an individual prescription and have not gone through FDA review for safety, effectiveness, or manufacturing consistency. Compounding pharmacies remain regulated by state boards, so oversight exists even without product approval.
Which one should I ask my provider about?
Bringing symptoms rather than a compound name to your provider tends to produce a better evaluation, because the clinical question is what is causing the symptom, not which peptide to buy. A licensed clinician orders labs, reviews your history, and may conclude that no peptide is appropriate. Walking in asking for a specific vial narrows the conversation before it starts.
The honest summary
Sermorelin and ipamorelin are two different tools that happen to point at the same gland, one through the GHRH receptor and one through the ghrelin receptor. Sermorelin carries the longer human research history for its mechanism class, while a meaningful share of what is claimed for ipamorelin still rests on preclinical work and small early-phase studies. Honest comparison means naming that asymmetry rather than presenting both as equally established.
Neither compound is an FDA-approved product in the form sold for adult wellness use, and neither is something to source outside a licensed prescriber and pharmacy. Restoration, not transcendence, is the reasonable expectation here: these are modest tools layered onto sleep, training, and everything else that actually moves the same systems. Anyone promising a number or a timeline is selling something the evidence does not support.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998. PMID 9849822.
Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides. 1985. PMID 2866496.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology. 2026. PMID 42395176.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.